Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
1.320
+0.010 (0.76%)
At close: Oct 9, 2025, 4:00 PM EDT
1.320
0.00 (0.00%)
After-hours: Oct 9, 2025, 4:00 PM EDT
Kairos Pharma Employees
As of December 31, 2024, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees.
Employees
4
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,177,750
Market Cap
27.38M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KAPA News
- 2 days ago - Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 - Business Wire
- 21 days ago - Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year - Business Wire
- 4 weeks ago - Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer - Business Wire
- 5 weeks ago - Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025 - Business Wire
- 5 weeks ago - Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 2 months ago - CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline - Newsfile Corp
- 3 months ago - Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 - Business Wire
- 3 months ago - Why Is Kairos Pharma Stock Surging On Tuesday? - Benzinga